一个自我激活和保护模块增强了全原抗CD70CAR-T细胞的临床前性能

Zhao Zhang1, Lianfeng Zhao1, Tinghui Huang1

  • 1Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, Nanjing, China.

Frontiers in immunology
|February 5, 2025
PubMed
概括

全球CAR-T (UCAR-T) 疗法显示出前景,但面临免疫排斥和耐用性问题. 一种新型的自我激活和保护 (SAP) 模块增强了UCAR-T细胞的生存和功能,克服了潜在的现成细胞疗法的这些局限性.